As of May 28th, RudaCure Inc. was selected for the Ministry of Trade, Industry and Energy's (Announcement No. 2020-145, March 6, 2020) 2020 R&D Rediscovery Project new evaluation for the project titled [Development of source technology for dry eye disease treatment using Rac1 inhibitor RCI001 for regulatory approval]. RudaCure is the lead institution, with detailed institutions Gil Medical Foundation and IP Darae Strategy Commercialization Center, with a total project budget of KRW 350 million per year. The company will spend the next year developing raw material pharmaceutical production methods and standards and testing methods for RCI001.